InspireMD Inc.宣布,其独创的Cguard输送系统已获得美国食品药品监督管理局(FDA)的批准,预计将于2026年第三季度正式在美国上市销售。
InspireMD Inc.宣布,其独创的Cguard输送系统已获得美国食品药品监督管理局(FDA)的批准,预计将于2026年第三季度正式在美国上市销售。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.